BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results

BASEL, Switzerland, BEIJING, & CAMBRIDGE, Mass., August 02, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results from the second quarter of 2023 and business highlights.

Related Keywords

Beijing ,China ,Australia ,Canada ,Suzhou ,Jiangsu ,Cambridge ,Cambridgeshire ,United Kingdom ,Japan ,United States ,Guangzhou ,Guangdong ,America ,American ,Johnv Oyler ,Luye Pharma ,Liza Heapes ,European Hematology Association ,Beigene Ltd ,Australia Therapeutic Goods Administration ,Genentech Inc ,Health Canada ,Development Programs ,Committee For Medicinal Products Human Use ,Dmax Foundation ,China National Medicinal Products Administration ,Amgen ,Luye Pharma Group Ltd ,Exchange Commission ,Drug Administration ,Novartis ,European Medicines Agency ,European Society Of Medical Oncology ,Scientific Congress Updates ,American Society Of Clinical Oncology ,Beigene Foundation ,Business Wire ,Medicinal Products ,Human Use ,Prescription Drug User Fee Act ,Antibody Drug Conjugate ,American Depositary Share ,Cash Equivalents ,Restricted Cash ,Short Term Investments ,Second Quarter ,Quarterly Report ,Goserelin Microspheres ,Lung Cancer ,Solid Tumor ,European Society ,Medical Oncology ,Annual Meeting ,American Society ,Clinical Oncology ,Princeton West Innovation Campus ,License Agreement ,North America ,Condensed Consolidated Balance Sheet Data ,Consolidated Statements ,American Depositary Shares ,Condensed Consolidated Financial Statements ,Significant Accounting ,Prior Period Financial ,Private Securities Litigation Reform Act ,Luye Pharma Group ,Adult Patients ,Beigene ,Global Biotechnology Company ,Wall ,